Of the approved agents, T-DXd stands out as it showed unparalleled efficacy in previously treated HER2+ BC in the DESTINY-Breast01/02 trials (8, 9) and was superior to T-DM1 in the DESTINY-Breast03 (10). This evidence concerns the gene ERBB2 and breast cancer.